Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
High inter-patient variability and high spatial heterogeneity are features of colorectal cancer (CRC). This may influence the molecular characterization of tumor tissue, now mandatory for patients with metastatic CRC who are candidates for treatment with an anti-EGFR mAb, as false-negative results can occur, leading to non optimal therapy. Moreover, temporal molecular heterogeneity during treatment is known to influence the response to therapy and prognosis. We present a literature overview of advances made in characterizing molecular heterogeneity in CRC, underlining that the analysis of liquid biopsy could represent an efficient non-invasive tool to overcome the problem. We believe that understanding CRC heterogeneity is fundamental for a more accurate diagnosis, for selecting the best targets to ensure prolonged antitumor response, and for monitoring minimal residual disease and the onset of resistance to therapy, all essential components of successful personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Heterogeneity, or more specifically, the diverse cell populations within the diseased tissue, is the leading cause of treatment failure for many complex diseases, such as cancers1, Alzheimer’s disease2, stroke3, and coronavirus disease 2019 (COVID-19)4, etc., as well as a major obstacle to successful precision medicine5–7.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“The majority of sporadic CRCs (almost 85%) arise from adenomas according to the model proposed by Fearon and Vogelstein in 1990 [16].”
BackgroundSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863 · cited 2×
“Finally, distinct mutations can also co-exist within the cells of a single metastatic lesion [7].”
BackgroundGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 1×
“to classify CRCs into four subtypes [12,22,29].”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 2×
“In Europe the overall survival (OS) rate for mCRC is estimated at 12%, with a median OS of 30 months [3].”
BackgroundClonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · cited 1×
“The lack of accurate standard methods to assess ITH is currently limiting our ability to explore its clinical implications [39].”
BackgroundIntra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000 · cited 1×
“In fact, a higher spatial and temporal variability of tumor microenvironment components, such as stromal, inflammatory, and microbial cells, may translate into a higher phenotypic heterogeneity of tumor cells [30].”
Background
Cited by
Bhat, A. A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C. P., Sharma, A., Maacha, S., Karedath, T., Hashem, S., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12295 · Cited by 229
Refining colorectal cancer classification and clinical stratification through a single-cell atlas
Khaliq, A. M., Erdogan, C., Kurt, Z., Turgut, S. S., Grunvald, M. W., Rand, T., Khare, S., Borgia, J. A., Hayden, D. M., Pappas, S. G., et al. (2022) · Genome Biology · doi:10.1186/s13059-022-02677-z · Cited by 214
“Approximately one third of patients experience disease relapse following curative-intent surgical resection and chemotherapy [2, 3].”
BackgroundPromising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials
Krasteva, N. A., & Georgieva, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061213 · Cited by 161
“CRC most often starts when cells in a polyp begin growing abnormally [49].”
BackgroundLoupakis, F., Sharma, S., Derouazi, M., Murgioni, S., Biason, P., Rizzato, M. D., Rasola, C., Renner, D., Shchegrova, S., Koyen Malashevich, A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00101 · Cited by 130
“Of note, the design of Natera’s mPCR-NGS assay considers clonal heterogeneity, which is a common characteristic of mCRC.(28,29) By contrast, orthogonal ctDNA detection tests such as ddPCR are designed to detect fewer tumor-specific SNVs at a time, providing less coverage for tumor heterogeneity.”
MethodLiao, C., Yu, Y.-L., Lin, Y., Hsu, Y., Chern, Y., Chiang, J., & You, J. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02253-y · Cited by 130
“Because of the heterogeneous nature of CRC, the treatment strategy and outcomes are diverse, even for tumors with the same stage [2].”
BackgroundPatient-specific Boolean models of signalling networks guide personalised treatments
Montagud, A., Béal, J., Tobalina, L., Traynard, P., Subramanian, V., Szalai, B., Alföldi, R., Puskás, L. G., Valencia, A., Barillot, E., et al. (2022) · eLife · doi:10.7554/elife.72626 · Cited by 101
“Our methodology suggests treatments for individual patients, but the obtained results vary greatly from patient to patient, which is not an uncommon issue of personalised medicine (Ciccarese et al., 2017; Molinari et al., 2018).”
BackgroundTargeting Invasion: The Role of MMP-2 and MMP-9 Inhibition in Colorectal Cancer Therapy
Shoari, A., Ardalan, A. A., Dimesa, A. M., & Coban, M. (2024) · Biomolecules · doi:10.3390/biom15010035 · Cited by 99
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 97
“In CRC, tumor heterogeneity was associated with worse prognosis and patient outcomes [30,32].”
BackgroundKasprzak, A., & Adamek, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194915 · Cited by 87
Artificial Intelligence and Precision Medicine: A New Frontier for the Treatment of Brain Tumors
Philip, A. K., Samuel, B., Bhatia, S., Khalifa, S. A. M., & El-Seedi, H. R. (2022) · Life · doi:10.3390/life13010024 · Cited by 76
“However, PM faces challenges due to the involvement of patient data, which includes data for disease, population diversity, and ethical reflections [42].”
BackgroundTRP Channels in Digestive Tract Cancers
Stokłosa, P., Borgström, A., Kappel, S., & Peinelt, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051877 · Cited by 75
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 67
Fernandes, E., Sores, J., Cotton, S., Peixoto, A., Ferreira, D., Freitas, R., Reis, C. A., Santos, L. L., & Ferreira, J. A. (2020) · Theranostics · doi:10.7150/thno.42480 · Cited by 68
“Moreover, patient management is further aggravated by the molecular heterogeneity presented by gastroesophageal and colorectal tumors, even between lesions of apparently similar histological nature [3-5] (Figure 1).”
BackgroundEpigenetic Landscape of Liquid Biopsy in Colorectal Cancer
Rodríguez‐Casanova, A., Costa‐Fraga, N., Bao‐Caamano, A., López‐López, R., Muinelo‐Romay, L., & Díaz‐Lagares, Á. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.622459 · Cited by 62
“Importantly, a refined understanding of the molecular aspects of CRC has recently been achieved owing to the application of next generation sequencing (NGS)-based approaches, which revealed a wide intratumor heterogeneity and general genomic instability (Molinari et al., 2018).”
BackgroundSammarco, G., Gallo, G., Vescio, G., Picciariello, A., Paola, G. D., Trompetto, M., Currò, G., & Ammendola, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092852 · Cited by 61
“Colorectal cancer (CRC) is a heterogeneous disease [1], molecularly and anatomically [2], that develops in a multi-step process [3] requiring the accumulation of several genetic or epigenetic mutations that lead to the gradual transformation of normal mucosa into cancer.”
BackgroundLuchini, C., Veronese, N., Nottegar, A., Cappelletti, V., Daidone, M. G., Smith, L., Parris, C. N., Brosens, L. A. A., Caruso, M. G., Cheng, L., et al. (2019) · Cancers · doi:10.3390/cancers11081152 · Cited by 66
ASGARD is a single-cell guided pipeline to aid repurposing of drugs
He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57
Sarshekeh, A. M., Alshenaifi, J. Y., Roszik, J., Manyam, G. C., Advani, S., Katkhuda, R., Verma, A., Lam, M. S., Willis, J. A., Shen, J. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2404 · Cited by 60
“MSS colorectal cancer is a heterogeneous disease (4) and one approach to develop new treatment strategies is to discover novel biomarkers identifying subsets of patients with the immunologically active microenvironment.”
BackgroundKazakova, E., Rakina, M. A., Sudarskikh, T., Iamshchikov, P. S., Тарасова, А. С., Таширева, Л. А., Afanasiev, S. G., Dobrodeev, А. Y., Zhuikova, L. D., Чердынцева, Н. В., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1058337 · Cited by 56
“Frontiers in Oncology 06 lymph node metastasis, multivariate Cox regression analysis revealed that increased SPARC mRNA expression remained an independent prognostic factor for poor DSS (HR=6,65; 95% CI [2,208-20,100], p=0,0007) and poor PFS (HR=1,88; 95% CI [1,1443,120], p=0,001) in CRC patients (Table 3).”
BackgroundMacháčková, T., Vychytilová-Faltejsková, P., Součková, K., Trachtová, K., Brchnelová, D., Svoboda, M., Kišš, I., Procházka, V., Kala, Z., & Slabý, O. (2020) · Cancers · doi:10.3390/cancers12123518 · Cited by 59
“New molecules involved in the process are continuously discovered [5].”
BackgroundKoustas, E., Sarantis, P., Kyriakopoulou, G., Papavassiliou, A. G., & Karamouzis, M. V. (2019) · Cancers · doi:10.3390/cancers11040533 · Cited by 54
“One section of a tumor might be dense with cells containing a particular oncogene mutation, whereas another section might have vastly different mutation backgrounds driving their growth [28].”
BackgroundMultifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer
Akbarzadeh-Khiavi, M., Safary, A., Barar, J., Ajoolabady, A., Somi, M. H., & Omidi, Y. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03305-z · Cited by 48
Genetic Alterations of Metastatic Colorectal Cancer
Testa, U., Castelli, G., & Pelosi, E. (2020) · Biomedicines · doi:10.3390/biomedicines8100414 · Cited by 44
“Several studies have shown that CRCs display a consistent degree of spatial intratumor heterogeneity; particularly, three types of spatial heterogeneity of CRCs have been described: (i) ITH related to the existence of genetic differences at the level of tumor cells within the primary tumor; (ii) ITH related to differe…”
BackgroundLarionova, I., Patysheva, M. R., Iamshchikov, P. S., Kazakova, E., Казакова, А., Rakina, M. A., Grigoryeva, E. S., Тарасова, А. С., Afanasiev, S. G., Bezgodova, N. V., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1080501 · Cited by 45
“CD14+CD16+CCR2+,% 18,04 (11,88-41,84) 18,95 (10,77-48,47) 23,48 (6,55-51,85) 10,17 (2,96-18,55)”
BackgroundMethodInfluentialZhu, X., Tian, X., Ji, L., Zhang, X., Cao, Y., Shen, C., Hu, Y., Wong, J. W. H., Fang, J.-Y., Hong, J., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00142-x · Cited by 41
Fattahi, F., Zanjani, L. S., Shams, Z. H., Kiani, J., Mehrazma, M., Najafi, M., & Madjd, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-92720-z · Cited by 45
The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis
Wu, Y., Hong, Q., Lu, F. Y., Zhang, Z., Li, J., Nie, Z., & He, B. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00641-6 · Cited by 44
Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine
Masucci, M. M., Ernberg, I., Karlsson, C., & Blomqvist, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14060561 · Cited by 42
“The effect of cancer heterogeneity on cancer treatments and personalized cancer medicine is significant because it can lead to treatment resistance, recurrence, and therapeutic failure [40,41].”
BackgroundDurán‐Vinet, B., Araya‐Castro, K., Calderón, J. F., Vergara, L. F., Weber, H. L., Retamales, J., Araya-Castro, P., & Leal, P. (2021) · Cancers · doi:10.3390/cancers13184640 · Cited by 40
“Thereby, molecular diagnosis has risen as a swift and affordable route to obtain an early CRC diagnosis [53], to be followed by suitable treatments, including chemotherapy [54], radiotherapy [55], immunotherapy [56], targeted therapy [57], and other therapies (further reading can be found in [9,58,59]), thus ultimatel…”
BackgroundBoccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100506 · Cited by 40
“Liver metastases 76 (57) 25 (69) 51 (53) Peritoneal metastases 73 (55) 18 (50) 55 (57) Primary tumor resected, n (%) 104 (78) 30 (83) 74 (76) Prior lines of therapy, n (%) 0 4 (3) 0 (0) 4 (4) 1 85 (64) 22 (61) 63 (65) 2 34 (26) 9 (25) 25 (26) 3 5 (4) 2 (6) 3 (3) 4 5 (4) 3 (8) 2 (2) Prior oxaliplatin, n (%) 122 (92) 34…”
Self-citationDing, X., Zhang, J., Feng, Z., Tang, Q., & Zhou, X. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06518-6 · Cited by 39
Horvat, N. D. S. M. R., Veeraraghavan, H., Nahas, C. S. R., Bates, . D. B., Ferreira, F., Zheng, J., Capanu, M., Fuqua, J. L., Fernandes, M. C., Sosa, R. E., et al. (2022) · Abdominal Radiology · doi:10.1007/s00261-022-03572-8 · Cited by 41
“Our results are in line with previous studies which demonstrated worse outcomes in patients with higher intratumoral heterogeneity, including poorer treatment response [41, 42].”
ResultColorectal cancer and therapy response: a focus on the main mechanisms involved
Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A. M., Almonti, V., & Vernazza, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1208140 · Cited by 42
“Frontiers in Oncology 04 Instead, left-sided CRC is characterized by CIN and the activation of the EGFR pathway (54).”
BackgroundMiao, D., Wang, Y., Jia, Y., Tong, J., Jiang, S., & Liu, L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110200 · Cited by 35
Pergolizzi, M., Bizzozero, L., Maione, F., Maldi, E., Isella, C., Macagno, M., Mariella, E., Bardelli, A., Médico, E., Marchiò, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02465-4 · Cited by 36
“Colorectal cancer (CRC) is a multifaceted and highly heterogeneous disease both at the inter-patient and intra-tumoral levels [8].”
BackgroundPersonalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 37
“CRC is one of the cancers with high heterogeneity among patients and even within a tumor, which has challenged the treatment of this disease (6).”
BackgroundInfluentialMohammed, M., Mboya, I. B., Mwambi, H. G., Elbashir, M. K., & Omolo, B. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261625 · Cited by 40
Hameed, Y., Usman, M., Liang, S., & Ejaz, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256020 · Cited by 33
KMT9 Controls Stemness and Growth of Colorectal Cancer
Berlin, C., Cottard, F., Willmann, D., Urban, S., Tirier, S. M., Marx, L., Rippe, K., Schmitt, M., Petrocelli, V., Greten, F. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1261 · Cited by 33
“To date, it is well accepted that the interpatient heterogeneity of colorectal cancer has clinical implications on therapeutic responses (48).”
BackgroundErve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 33
Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer
Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 34
“Nevertheless, their utility remains a topic of debate, and the genetic alterations confined to the RAS and BRAF mutation spectrum remain the most extensively investigated markers [37].”
Wen, R., Zhou, L., Peng, Z., Fan, H., Zhang, T., Jia, H., Gao, X., Hao, L., Lou, Z., Cao, F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1175343 · Cited by 28
“CRC intra-tumor heterogeneity (ITH) may also occur due to differences in cancer cells and TME within the tumor, further complicating the development of new therapeutic strategies and biomarker identification (33).”
BackgroundExploring the Interdisciplinary Nature of Precision Medicine:Network Analysis and Visualization
Xu, X., Hu, J., Lyu, X., Huang, H., & Cheng, X. (2020) · JMIR Medical Informatics · doi:10.2196/23562 · Cited by 27
“Precision medicine also faces many challenges, such as disease heterogeneity, diverse populations, and ethical considerations [6-9].”
Cordycepin inhibits colon cancer proliferation by suppressing MYC expression
Zhang, Z., Li, K., Zheng, Z. G., & Liu, Y. (2022) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-022-00551-z · Cited by 26
“The high inter-patient variability, manifested by genomic heterogeneity, makes targeted therapies less reliable [3, 4].”
BackgroundDiagnósticos de enfermagem em pacientes acometidos pela COVID-19
CURSOS, L. C. E. &., Silva, T. D. C., Queiroz, M. D. O., Vieira, T. D. A., Monteiro, G. B. S., Ribeiro, L. M., & Naka, K. S. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/20 · Cited by 24
Assistência de enfermagem a pacientes críticos em cuidados paliativos: revisão integrativa
CURSOS, L. C. E. &., Costa, B. H. S., Pereira, M. F., Maria, T. E. M. D. S., Ferreira, J. C. D. S., da Silva, L. D. S. M., da Paz, M. S. S., de Oliveira, G. D. F., Dias, T. K. C., Dias, K. G. C., et al. (2022) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-12-3/18 · Cited by 24
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 30
Fan, Y., Xiang, S., Dai, Z., Zou, C., Wang, X., & Gao, Z. (2019) · International Journal of Colorectal Disease · doi:10.1007/s00384-019-03299-x · Cited by 24
“Colorectal cancer is characterized by high inter-patient heterogeneity, which is a challenge for personalized medicine [3].”
BackgroundPrognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients
Nikolić, N., Radosavljevic, D. Z., Gavrilović, D., Nikolić, V., Stanic, N., Spasić, J., Čaćev, T., Castellvı́-Bel, S., Cavic, M. R., & Janković, G. (2021) · Medicina · doi:10.3390/medicina57101108 · Cited by 24
“Management of advanced CRC is mainly oriented on the recognition of advanced CRC patients as a heterogeneous patient population and, consequently, to a “clinical and molecular” personalized therapy [17,18].”
BackgroundSchurink, N. W., van Kranen, S. R., Berbée, M., van Elmpt, W., Bakers, F. C. H., Roberti, S., van Griethuysen, J. J. M., Min, L. A., Lahaye, M. J., Maas, M., et al. (2021) · European Radiology · doi:10.1007/s00330-021-07724-0 · Cited by 27
Abumustafa, W., Zamer, B. A., Khalil, B. A., Hamad, M. A., Maghazachi, A. A., & Muhammad, J. S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112368 · Cited by 27
He, J., & Wu, W. (2022) · Non-coding RNA Research · doi:10.1016/j.ncrna.2022.10.001 · Cited by 23
“However, there is a high degree of spatial heterogeneity and variability among patients in CRC [204].”
BackgroundNew developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 24
Zhang, R., Li, T., Wang, W., Gan, W., Lv, S., Zeng, Z., Hou, Y., Yan, Z., & Yang, M. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594098 · Cited by 24
Improving the overall survival prognosis prediction accuracy: A 9‐gene signature in CRC patients
Zheng, W., Lu, Y., Feng, X., Yang, C., Qiu, L., Deng, H., Xue, Q., & Sun, K. (2021) · Cancer Medicine · doi:10.1002/cam4.4104 · Cited by 22
Zhou, R., Xie, F., Liu, K., Zhou, X., Chen, X., Chen, J., Xi, S., Huang, Z., & Rong, X. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01290-y · Cited by 22
Sharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 27
“Tumor heterogeneity adds another layer of complexity, contributing to treatment resistance and variability in patient responses[20,21].”
Al‐Harazi, O., Kaya, I. H., Allali, A. E., & Çolak, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.721949 · Cited by 24
Jiang, T., Zheng, J., Li, N., Li, X., He, J., Zhou, J., Sun, B., & Chi, Q. (2024) · Current Gene Therapy · doi:10.2174/0115665232294568240201073417 · Cited by 23
Kasprzak, A., Seraszek‐Jaros, A., Jagielska, J., Helak-Łapaj, C., Siodła, E., Szmeja, J., & Kaczmarek, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184580 · Cited by 21
“CRC is characterized by high inter-patient and intra-tumor heterogeneity, as well as temporal molecular heterogeneity during treatment, which is known to influence the response to therapy and prognosis [3].”
BackgroundPedersen, S. K., Symonds, E. L., Roy, A. C., Cornthwaite, K. J., LaPointe, L. C., & Young, G. P. (2022) · Cancer Medicine · doi:10.1002/cam4.5008 · Cited by 23
Padoan, A., & Plebani, M. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0517 · Cited by 22
“Pathology and liquid biopsy could serve for determining tumor heterogeneity and evolution, particularly in light of the intra-patient variability observed in the invasiveness of di ff erent metastases within the same patient [22, 23].”
BackgroundA Claudin-Based Molecular Signature Identifies High-Risk, Chemoresistant Colorectal Cancer Patients
Gowrikumar, S., Primeaux, M., Pravoverov, K., Wu, C., Szeglin, B. C., Sauvé, C.-E. G., Thapa, I., Bastola, D. K., Chen, X., Smith, J. J., et al. (2021) · Cells · doi:10.3390/cells10092211 · Cited by 20
“Furthermore, variation in treatment responses has made optimizing patient care strategies particularly challenging, as there is not yet an accurate method for predicting response to chemotherapy or recurrence risks in CRC patients [3].”
MethodLost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer
Iyer, K. K., van Erp, N. P., Tauriello, D. V. F., Verheul, H. M. W., & Poel, D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102466 · Cited by 20
“Inherent tumour heterogeneity and the presence of drug resistant genetic clones within tumour cells could be a cause behind the intrinsic resistance in CRC [79,80].”
Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Urbini, M., Marisi, G., Azzali, I., Bartolini, G., Chiadini, E., Capelli, L., Tedaldi, G., Angeli, D., Canale, M., Molinari, C., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00694 · Cited by 25
“8 characterizing tumors.”
Self-citationBerrino, E., Balsamo, A., Pisacane, A. M., Gallo, S., Becco, P., Miglio, U., Caravelli, D., Poletto, S., Paruzzo, L., Debernardi, C., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100133 · Cited by 21
“12 We previously reported a sun-exposure-dependent distribution of the BRAF p.V600E mutation in either nevi or melanocytic lesions, thus suggesting that this oncogene variant may not be clonally selected in melanoma progression.”
Poonpanichakul, T., Shiao, M., Jiravejchakul, N., Matangkasombut, P., Sirachainan, E., Charoensawan, V., & Jinawath, N. (2021) · Bioscience Reports · doi:10.1042/bsr20212093 · Cited by 20
“However, overall progress is still largely hindered by the limitations of resolving intratumoural heterogeneity, and hence the majority of the expression profiles represent the ‘average’ molecular characteristics of highly heterogeneous cancer cells [15,16].”
Jain, A. K., Morris, M. T., Berardi, D., Arora, T., Domingo-Almenara, X., Paty, P. B., Rattray, N. J. W., Kerekes, D. M., Lu, L., Khan, S. A., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02133-5 · Cited by 20
“If not addressed, subsite-associated variability may contribute to the failure of mechanism-targeted therapies for CRC as well as poor accuracy of potential CRC biomarkers [10].”
BackgroundHou, Y., Wang, W., Zeng, Z., Gan, W., Lv, S., Li, T., Yan, Z., Zhang, R., & Yang, M. H. (2020) · Aging · doi:10.18632/aging.104038 · Cited by 21
Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases
Wong, G. Y. M., Diakos, C. I., Hugh, T. J., & Molloy, M. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116091 · Cited by 19
Gmeiner, W. H. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s242224 · Cited by 18
“ing may yield ambiguous results with tumor heterogeneity a confounding factor.(22) Further, acquired resistance to anti-EGFR therapy is also a serious concern.”
BackgroundLi, C., Cai, D., Zhong, M., Lv, M., Huang, Z.-P., Zhu, Q., Hu, C., Qi, H., Wu, X., & Gao, F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.880093 · Cited by 19
“Even with the same clinical stage, patients may be suitable to different treatment options before and after surgery as heterogeneity of CRC (Molinari et al., 2018).”
BackgroundRobles, J., Prakash, A., Vizcaíno, J. A., & Casal, J. I. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011828 · Cited by 18
Hezi, H., Gelber, M., Balabanov, A., Maruvka, Y. E., & Freiman, M. (2024) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2024.108513 · Cited by 18
Marbun, V. M. G., Erlina, L., & Lalisang, T. J. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267090 · Cited by 26
Kasahara, K., Katsumata, K., Saito, A., Ishizaki, T., Enomoto, M., Mazaki, J., Tago, T., Nagakawa, Y., Matsubayashi, J., Nagao, T., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02209-6 · Cited by 19
“This is an extremely difficult assessment method and is ethically almost impossible to apply clinically [20].”
MethodNarayan, S., Courcoubetis, G., Mason, J. M., Naghdloo, A., Kolenčík, D., Patterson, S. D., Kühn, P., & Shishido, S. N. (2022) · Cancers · doi:10.3390/cancers14194891 · Cited by 19
Li, J., Wang, X., Cai, L., Sun, J., Yang, Z., Liu, W., Wang, Z., & Lv, H. (2023) · Cancer Medicine · doi:10.1002/cam4.6523 · Cited by 18
Lv, M., Cai, D., Li, C., Chen, J., Li, G., Hu, C., Gai, B., Lei, J., Lan, P., Wu, X., et al. (2023) · MedComm · doi:10.1002/mco2.333 · Cited by 17
Borelli, B., Fontana, E., Giordano, M., Antoniotti, C., Lonardi, S., Bergamo, F., Pietrantonio, F., Morano, F., Tamburini, E., Boccaccino, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100073 · Cited by 20
Self-citationVivarelli, S., Falzone, L., Candido, S., Bonavida, B., & Libra, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168481 · Cited by 16
“Given the high intrinsic genomic instability, CRC shows an elevated inter-patient and intra-tumor heterogeneity, both associated with poorer outcomes [3].”
BackgroundYeoh, Y., Low, T. Y., Abu, N., & Lee, P. Y. (2021) · PeerJ · doi:10.7717/peerj.12338 · Cited by 18
Mishra, S., Srivastava, P., Pandey, A., Shukla, S., Agarwal, A., & Husain, N. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100301 · Cited by 16
Palazzolo, G., Mollica, H., Lusi, V., Rutigliani, M., Francesco, M. D., Pereira, R. C., Filauro, M., Paleari, L., DeCensi, A., & Decuzzi, P. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100760 · Cited by 17
“This is probably due to the high variability among different patients in terms of gene expression and mutation profiles, as reported in the literature [39].”
BackgroundResultÁrnadóttir, S. S., Mattesen, T. B., Vang, S., Madsen, M. R., Madsen, A. H., Birkbak, N. J., Bramsen, J. B., & Andersen, C. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241148 · Cited by 16
“It has been suggested that this heterogeneity complicates development of novel treatment strategies and biomarkers [6, 7].”
BackgroundZhuang, Q.-S., Sun, X., Chong, Q.-Y., Banerjee, A., Zhang, M., Wu, Z., Zhu, T., Pandey, V., & Lobie, P. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712348 · Cited by 14
Giarrizzo, M., LaComb, J. F., Patel, H. R., Reddy, R. G., Haley, J. D., Graves, L. M., Iwanowicz, E. J., & Bialkowska, A. B. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0170 · Cited by 15
Vé, O., Ashykhmin, A., Golovko, T., Rykhalskyi, O., & Orel, V. B. (2021) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001218 · Cited by 14
“An assessment of intratumoral and peritumoral heterogeneity should therefore be considered to developmore personalized strategies for rectal cancer treatment.(10,36) Interpretation of texture parameters based on PET/CT hybrid imaging raises questions about the role of FDG in the analysis of heterogeneity in the tumor…”
BackgroundŽilinskas, J., Stukas, D., Jasukaitienė, A., Šapauskienė, J., Banienė, R., Trumbeckaitė, S., Švagždys, S., Cicciù, M., Dambrauskas, Ž., Gulbinas, A., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04777-0 · Cited by 13
Hatthakarnkul, P., Quinn, J. A., Ammar, A., Lynch, G., van Wyk, H., McMillan, D., Thuwajit, C., & Edwards, J. (2022) · Clinical Science · doi:10.1042/cs20210886 · Cited by 15
A novel multi-task linear mixed model for smartphone-based telemonitoring
Yoon, H., & Gaw, N. B. (2020) · Expert Systems with Applications · doi:10.1016/j.eswa.2020.113809 · Cited by 13
Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer
Oh, I. H., Pyo, J., & Son, B. K. (2021) · Current Oncology · doi:10.3390/curroncol28040274 · Cited by 13
“Moreover, high heterogeneity in CRC is widely known to affect tumor progression and treatment resistance [2].”
BackgroundBiomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?
Diener, M. K., & Fichtner‐Feigl, S. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12454 · Cited by 12
Ceccon, C., Angerilli, V., Rasola, C., Procaccio, L., Sabbadin, M., Bergamo, F., Malapelle, U., Lonardi, S., & Fassan, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.930108 · Cited by 12
Nanoformulations of Plant-Derived Compounds as Emerging Therapeutic Approach for Colorectal Cancer
Biganeh, H., Dizaji, S. M., Taghipour, Y. D., Murtaza, G., & Rahimi, R. (2022) · Current Drug Delivery · doi:10.2174/1567201819666220823155526 · Cited by 12
Robles, J., Pintado‐Berninches, L., Boukich, I., Escudero, B., Ríos, V. D. L., Bartolomé, R. A., Jaén, M., Martín‐Regalado, Á., Fernández‐Aceñero, M. J., Imbaud, J. I., et al. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.294 · Cited by 14
“This heterogeneity is reflected in differential epigenetic and genetic events such as microsatellite and chromosomal instability (MSI and CIN), CpG island methylator phenotype (CIMP), and TP53, KRAS, and BRAF mutations (among others) that lead to different pathogenesis and drug sensitivity [3].”
BackgroundArteaga-Arteaga, H. B., Candamil-Cortés, M. S., Breaux, B., Guillen-Rondon, P., Orozco-Arias, S., & Tabares-Soto, R. (2023) · Briefings in Functional Genomics · doi:10.1093/bfgp/elad002 · Cited by 12
Simpson, G., Jin, W., Spieler, B., Portelance, L., Mellon, E., Kwon, D., Ford, J. C., & Dogan, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.807725 · Cited by 11
Nazempour, N., Taleqani, M. H., Taheri, N., Najafabadi, A. H., Shokrollahi, A., Zamani, A., Dolatabadi, N. F., Peymani, M., & Mahdevar, M. (2021) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2021.104688 · Cited by 11
Wang, J., Hu, J., Wang, M., Yuan, H., Xing, Y., Zhou, X., Ding, M., Chen, W., Qu, B., & Zhu, L. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10267-8 · Cited by 12
“Colorectal cancer (CRC) is a highly heterogeneous disease (Molinari et al. 2018).”
Background
Metadata
- Authors
- Molinari, C., Marisi, G., Passardi, A., Matteucci, L., De Maio, G., & Ulivi, P.
- Affiliations
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy
- Corresponding author
- Ulivi, Paola
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-23
- Volume
- 19
- Issue
- 12
- Pages
- 3733
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6321493
- OpenAlex
- W2901481287
- Cited by
- 262
- References
- 116
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 30 · 2023: 25 · 2022: 84 · 2021: 49 · 2020: 20 · 2019: 9
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, tumor heterogeneity, spatial heterogeneity, interpatient variability, metastatic colorectal cancer, anti-EGFR monoclonal antibody, liquid biopsy, minimal residual disease, treatment resistance, personalized medicine, molecular characterization
- MeSH terms
- Liquid Biopsy, Biological Variation, Individual, Humans, Neoplasm Metastasis, Neoplasm Staging, Biomarkers, Tumor, Colorectal Neoplasms, Genetic Heterogeneity, Molecular Diagnostic Techniques, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.